
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in pat... Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 2.11 | 2.11 | 2.11 | 0 | 0 | CS |
4 | 0 | 0 | 2.11 | 2.11 | 2.11 | 0 | 0 | CS |
12 | 0 | 0 | 2.11 | 2.11 | 2.11 | 0 | 0 | CS |
26 | 0.03 | 1.44230769231 | 2.08 | 2.4 | 1.69 | 20657 | 2.13298575 | CS |
52 | -1.09 | -34.0625 | 3.2 | 4.4 | 1.61 | 48965 | 2.83416207 | CS |
156 | -6.276 | -74.83901741 | 8.386 | 9 | 1.01 | 172666 | 4.15204696 | CS |
260 | -20.49 | -90.6637168142 | 22.6 | 49.4 | 1.01 | 540891 | 23.75446198 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions